Veana Therapeutics is a clinical-stage, research and development biotechnology company focused on creating innovative cancer immunotherapy technologies. The company's flagship product, Veana Immune Modulator, is a non-toxic adjuvant treatment designed to enhance the anti-tumor immune response, providing a safer and more effective option for cancer patients. Veana Therapeutics operates in the biotechnology sector, specifically targeting the oncology market. The company serves patients affected by various types of cancer, aiming to improve and extend their lives through advanced immunotherapy solutions. Veana Therapeutics generates revenue through the development and potential commercialization of its proprietary cancer treatments. The business model includes partnerships with healthcare providers, research institutions, and potential licensing agreements for its technologies.

Keywords: cancer immunotherapy, biotechnology, oncology, non-toxic treatment, adjuvant therapy, anti-tumor response, clinical-stage, research and development, innovative technologies, patient-focused.